When did Wall Street sour on Lilly’s Alzheimer’s drug?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with news that STAT+, our exclusive source for trusted and authoritative coverage of the life sciences, is on sale this week. Claim your exclusive offer now and save 40% with code STAT40.

Acadia’s schizophrenia drug fails in pivotal study

Acadia Pharmaceuticals’ treatment for schizophrenia missed its primary goal in a pivotal study, the company said yesterday, pointing to an unexpectedly strong placebo effect.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In